Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Needs More Resources, Good Leadership, Daschle Tells Senate Panel

This article was originally published in The Gray Sheet

Executive Summary

At a Jan. 8 confirmation hearing before the Senate Health, Education, Labor and Pensions Committee, HHS Secretary nominee Tom Daschle said that FDA needs more resources, better public policy and stronger leadership if it is to improve the device and drug approval processes and worker morale

You may also be interested in...



ODE Chief Tillman Defends 510(k) Program At Minnesota Industry Meeting

FDA's head of device evaluation is defending the agency's handling of 510(k) pre-market notification submissions in the face of criticism from two groups: those who charge the agency has allowed devices on the market without sufficient scientific evidence, and industry representatives who claim that FDA often demands too much from 510(k) applicants

“Ordered, Intimidated And Coerced”? CDRH Targeted In Misconduct Probe

FDA's device center has until Dec. 1 to respond to a Congressional inquiry into allegations of wrongdoing in its pre-market review process

Stakeholders Gather To Discuss Pandemic Response And Next Steps

As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT026976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel